RAFA LABORATORIES LTD


Associated tags: FIMI

Locations: ISRAEL

Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors

Retrieved on: 
Wednesday, March 20, 2024
Development, Poisoning, Organophosphate, VX, Status epilepticus, Patient, Nerve agent, Clothing, Laboratory, Human services, Atropine, Sarin, Administration, FDA

Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.

Key Points: 
  • Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.
  • Rafa Laboratories already manufactures adult atropine autoinjectors, FDA-approved in July 2018, and pediatric atropine autoinjectors authorized for use under FDA Emergency Use Authorization (EUA) in January 2018.
  • The new design for the pediatric atropine autoinjector, which is intended for civilian use, will incorporate a new needle shield mechanism feature.
  • To meet FDA approval requirements for the enhanced pediatric atropine autoinjector, BARDA will provide comprehensive support to Rafa Laboratories.

Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors

Retrieved on: 
Wednesday, March 20, 2024
Development, Poisoning, Organophosphate, VX, Status epilepticus, Patient, Nerve agent, Clothing, Laboratory, Human services, Atropine, Sarin, Administration, FDA

Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.

Key Points: 
  • Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.
  • Rafa Laboratories already manufactures adult atropine autoinjectors, FDA-approved in July 2018, and pediatric atropine autoinjectors authorized for use under FDA Emergency Use Authorization (EUA) in January 2018.
  • The new design for the pediatric atropine autoinjector, which is intended for civilian use, will incorporate a new needle shield mechanism feature.
  • To meet FDA approval requirements for the enhanced pediatric atropine autoinjector, BARDA will provide comprehensive support to Rafa Laboratories.